Instead of the painstaking process of developing new drugs, one Boston-based company is making its mark by pairing up those we already have. Meredith Wadman reports.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Related links
Related links
Related links in Nature Research
Multicomponent therapeutics for networked systems
Related external links
Stuart Schreiber of the Broad Institute
Julian Adams of Infinity Pharmaceuticals
For Tufts Center for the Study of Drug Development report
Angiotech Pharmaceuticals alliance with CombinatoRx
Rights and permissions
About this article
Cite this article
The right combination. Nature 439, 390–391 (2006). https://doi.org/10.1038/439390a
Published:
Issue Date:
DOI: https://doi.org/10.1038/439390a
